SKCPT
Appearance
![]() | The topic of this article may not meet Wikipedia's general notability guideline. (November 2023) |
SKCPT (SKI 306X) is a drug under development by SK Chemicals for the treatment of osteoarthritis. It is in a Phase III trial as of 2023.[1][2][3]
It is a purified extract from a mixture plants (Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris) which are each used in herbal medicine.[4]
References
[edit]- ^ https://www.globaldata.com/store/report/skcpt-in-osteoarthritis-loa-innovation-and-trend-analysis/. Retrieved 4 November 2023.
{{cite web}}
: Missing or empty|title=
(help) - ^ Kim, Hye-Min; Kang, Minseok; Jung, Yoon-Seok; Lee, Yoon-Jung; Choi, Wonjae; Yoo, Hunseung; Kim, JeongHoon; An, Hyo-Jin (January 2023). "Effects of SKCPT on Osteoarthritis in Beagle Meniscectomy and Cranial Cruciate Ligament Transection Models". International Journal of Molecular Sciences. 24 (19): 14972. doi:10.3390/ijms241914972. ISSN 1422-0067. PMC 10573642. PMID 37834419.
- ^ "SKCPT by SK Chemicals for Osteoarthritis: Likelihood of Approval". Pharmaceutical Technology. 31 July 2023. Retrieved 4 November 2023.
- ^ Jung, Young Bok; Roh, Kwon-Jae; Jung, Jin-A; Jung, Kiwon; Yoo, Hunseung; Cho, Yong-Baik; Kwak, Wie-Jong; Kim, Dae-Kee; Kim, Key H.; Han, Chang-Kyun (2001). "Effect of SKI 306X, a New Herbal Anti-Arthritic Agent, in Patients with Osteoarthritis of the Knee: A Double-Blind Placebo Controlled Study". The American Journal of Chinese Medicine. 29 (3n04): 485–491. doi:10.1142/S0192415X01000502. PMID 11789591.